Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany. manns.michael@ mh-hannover.de
Nat Rev Drug Discov. 2013 Aug;12(8):595-610. doi: 10.1038/nrd4050. Epub 2013 Jun 28.
Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research and development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, the way in which care is delivered is evolving at a breath-taking pace. Here, we review the current and upcoming treatment options for HCV, describe the key challenges facing clinicians and drug developers and discuss how the landscape in the HCV arena will change over the coming years.
在丙型肝炎病毒（HCV）被发现近 25 年后，经过激烈的研究和开发努力，大量直接作用抗病毒药物现在开始进入患者治疗。因此，护理方式正在以惊人的速度发展。在这里，我们回顾了 HCV 的当前和即将出现的治疗选择，描述了临床医生和药物开发者面临的关键挑战，并讨论了 HCV 领域的格局在未来几年将如何变化。
